<code id='3FD305EACF'></code><style id='3FD305EACF'></style>
      • <acronym id='3FD305EACF'></acronym>
      <center id='3FD305EACF'><center id='3FD305EACF'><tfoot id='3FD305EACF'></tfoot></center><abbr id='3FD305EACF'><dir id='3FD305EACF'><tfoot id='3FD305EACF'></tfoot><noframes id='3FD305EACF'>
      • <optgroup id='3FD305EACF'><strike id='3FD305EACF'><sup id='3FD305EACF'></sup></strike><code id='3FD305EACF'></code></optgroup>
        5. <b id='3FD305EACF'><label id='3FD305EACF'><select id='3FD305EACF'><dt id='3FD305EACF'><span id='3FD305EACF'></span></dt></select></label></b><u id='3FD305EACF'></u>
          <i id='3FD305EACF'><strike id='3FD305EACF'><tt id='3FD305EACF'><pre id='3FD305EACF'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-10-02 22:37:49 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：16612
                                  
                                    
          
                                   
          Adam's take main illustration
          Molly Ferguson/STAT
          Biotech is awash in PIPEs.
          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.
          advertisement
          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.
                                
                            
          Next article：  
                                      
                                          Medical leaders decry Supreme Court decision on affirmative action
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles